Comparative Pharmacology
Head-to-head clinical analysis: MD 76R versus RENOGRAFIN 76.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MD 76R versus RENOGRAFIN 76.
MD-76R vs RENOGRAFIN-76
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MD-76R is a radiopaque contrast agent that contains iodine, which attenuates X-rays, thereby enhancing the contrast of blood vessels and tissues during radiographic procedures. It functions by increasing the absorption of X-rays in areas where it is present, allowing for visualization of vascular structures and organ perfusion.
Radiopaque contrast agent that attenuates X-rays by absorbing them due to its high iodine content, allowing visualization of vascular structures and organs during radiographic procedures.
2–4 mL/kg intravenously, maximum 150 mL per procedure.
Intravenous administration of 50-100 mL (14.1-28.2 g iodine) as a single dose for angiography; dose varies by procedure and patient size.
None Documented
None Documented
Terminal half-life 1-2 hours; prolonged in renal impairment.
Terminal elimination half-life: 1–2 hours (normal renal function); prolonged to >20 hours in severe renal impairment (CrCl <10 mL/min)
Primarily renal; 95% eliminated unchanged in urine within 24 hours; <1% fecal.
Renal: >95% unchanged via glomerular filtration; biliary/fecal: negligible (<5%)
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent